Funding Opportunities
Learn more about D2R's newly launched funding programs.
Articles
In Martha Crago's recent article, she writes about how the rapid development of mRNA vaccines against SARS-CoV-2 testified to what can be accomplished when the world’s scientists put their minds together, with industry and governments investing to accelerate progress.
Events
Upcoming events include a Symposium Honoring the legacy of Jerry Pelletier on May 3, 2024.
D2R | DNA to RNA
An inclusive Canadian approach to genomic-based RNA therapeutics
The time is now for discovery and development of genome-guided, RNA-based precision medicines for Canada and for the world. With a landmark $165 million investment from the Canada First Research Excellence Fund, McGill’s world-leading research initiative DNA to RNA (D2R) will develop revolutionary genomic-based RNA medicines for all people of Canada.
Discover the initiative
D2R's vision for Canada
Create groundbreaking medical treatments
D2R will improve health through rapid deployment of new lower cost medical treatments for previously “undruggable” pharmaceutical targets and untreated medical conditions.Tackle societal and policy issues
D2R will address unmet clinical needs of under-served groups, including Canada’s Indigenous and immigrant populations by engaging with patients, their families and patient organizations.Accelerate “next-generation” drug development
D2R will catalyze Canadian pharma/biotech to create a major international hub for “next-generation” drug development, industry partnerships and startups.
Our researchers & partners
McGill researchers have been uncovering the mechanisms and potential of RNA for over 50 years. From genomics and RNA biology to medicine and biomanufacturing, our research strengths cover the range of expertise needed to discover gene targets and develop new treatments for disease.
